Clinical course of patients with severe SARS-CoV-2 infection co-treatment with Jin Si Herbal Tea in Eastern Taiwan: A retrospective cohort study
Coronavirus disease-2019 (COVID-19) has affected more than 608 million people and has killed 6.5 million people in the world. A few studies showed traditional Chinese medicine can be beneficial for COVID-19 treatment. An herbal preparation Jin Si Herbal Tea (JS) was formulated with herbal extracts k...
Gespeichert in:
| Veröffentlicht in: | Journal of herbal medicine 2022-12, Vol.36, p.100610-100610, Article 100610 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 100610 |
|---|---|
| container_issue | |
| container_start_page | 100610 |
| container_title | Journal of herbal medicine |
| container_volume | 36 |
| creator | Li, Pei-Chen Wang, Hui-Sheng Shibu, Marthandam Asokan Wang, Jhen Huang, Shiau-Huei Wang, Jeng-Hung Wang, Ji-Hung Huang, Chih-Yang Chiang, Chien-Yi Lin, Yu-Jung Ho, Tsung-Jung Lin, Shinn-Zong Chung, Hui-Chun Yu, Hsin-Yuan Su, San-Hua Chou, Ying-Fang Tai, Chia-Hui Ding, Dah-Ching Shih, Cheng Yen |
| description | Coronavirus disease-2019 (COVID-19) has affected more than 608 million people and has killed 6.5 million people in the world. A few studies showed traditional Chinese medicine can be beneficial for COVID-19 treatment. An herbal preparation Jin Si Herbal Tea (JS) was formulated with herbal extracts known for their potential to decrease spike protein and ACE2 interaction, 3CL, and TRPMSS2 protease activity, and thus aimed to evaluate the clinical course of JS co-treatment along with the usual treatment schedule given for severe COVID-19 patients.
This retrospective cohort study included patients with severe COVID-19 admitted to Hualien Tzu Chi Hospital between June and July 2021. All the patients were co-treated with JS and the primary outcome was death. The secondary outcomes included laboratory exam, Ct value, clinical course, and hospital stays. There were 10 patients recruited in this study and divided into |
| doi_str_mv | 10.1016/j.hermed.2022.100610 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9616512</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2210803322000793</els_id><sourcerecordid>2733202323</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-4b1c6946229a6d67ce88304a4c11a30d031d29b06588bd2fc09e5367c3b9f6113</originalsourceid><addsrcrecordid>eNp9kc1uEzEUhS0EolXpGyDkJZtJ_Rd3hgVSFBVaVAmJBLaWx3OHOJrYwfak6lvwyNxoSoAN3tiyzz3X536EvOZsxhnXV9vZBtIOuplgQuAV05w9I-dCcFbVTPHnp7OUZ-Qy5y3DpZlQjL8kZ1JLxZWen5Ofy8EH7-xAXRxTBhp7urfFQyiZPviyoRkOkICuFl9W1TJ-qwT1oQdXfAxYU5UEtuxQPqk_-UBXnt5CatFzDRbV9MbmAinQtfUPNryjC5qgpJj3R5sDoM0mpkJzGbvHV-RFb4cMl0_7Bfn64Wa9vK3uP3-8Wy7uK6e0LJVqudON0kI0Vnf62kFdS6ascpxbyTomeSealul5Xbed6B1rYC5RJ9um15zLC_J-8t2PLQ7SYYJkB7NPfmfTo4nWm39fgt-Y7_FgGs31nAs0ePtkkOKPEXIxO58dDIMNEMdsxLWUSEcKiVI1SR2Gzgn6UxvOzJGn2ZqJpznyNBNPLHvz9xdPRb_p_ckAOKiDh2SyQ3IOOp9wtKaL_v8dfgEhKrPH</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2733202323</pqid></control><display><type>article</type><title>Clinical course of patients with severe SARS-CoV-2 infection co-treatment with Jin Si Herbal Tea in Eastern Taiwan: A retrospective cohort study</title><source>Alma/SFX Local Collection</source><creator>Li, Pei-Chen ; Wang, Hui-Sheng ; Shibu, Marthandam Asokan ; Wang, Jhen ; Huang, Shiau-Huei ; Wang, Jeng-Hung ; Wang, Ji-Hung ; Huang, Chih-Yang ; Chiang, Chien-Yi ; Lin, Yu-Jung ; Ho, Tsung-Jung ; Lin, Shinn-Zong ; Chung, Hui-Chun ; Yu, Hsin-Yuan ; Su, San-Hua ; Chou, Ying-Fang ; Tai, Chia-Hui ; Ding, Dah-Ching ; Shih, Cheng Yen</creator><creatorcontrib>Li, Pei-Chen ; Wang, Hui-Sheng ; Shibu, Marthandam Asokan ; Wang, Jhen ; Huang, Shiau-Huei ; Wang, Jeng-Hung ; Wang, Ji-Hung ; Huang, Chih-Yang ; Chiang, Chien-Yi ; Lin, Yu-Jung ; Ho, Tsung-Jung ; Lin, Shinn-Zong ; Chung, Hui-Chun ; Yu, Hsin-Yuan ; Su, San-Hua ; Chou, Ying-Fang ; Tai, Chia-Hui ; Ding, Dah-Ching ; Shih, Cheng Yen</creatorcontrib><description>Coronavirus disease-2019 (COVID-19) has affected more than 608 million people and has killed 6.5 million people in the world. A few studies showed traditional Chinese medicine can be beneficial for COVID-19 treatment. An herbal preparation Jin Si Herbal Tea (JS) was formulated with herbal extracts known for their potential to decrease spike protein and ACE2 interaction, 3CL, and TRPMSS2 protease activity, and thus aimed to evaluate the clinical course of JS co-treatment along with the usual treatment schedule given for severe COVID-19 patients.
This retrospective cohort study included patients with severe COVID-19 admitted to Hualien Tzu Chi Hospital between June and July 2021. All the patients were co-treated with JS and the primary outcome was death. The secondary outcomes included laboratory exam, Ct value, clinical course, and hospital stays. There were 10 patients recruited in this study and divided into < 70 years and ≧ 70 years groups (n = 5 in each group).
Older patients (≧70 years) had a higher Charlson Comorbidity Index, VACO index, and lower hemoglobin levels than < 70 years patients. The trend of lymphocyte count, LDH, D-dimer, and Ct value of non-survivors was not consistent with previous studies. The death rate was 20% and the recovery rate to mild illness in 14 days was 40%.
In conclusion, this is the first clinical study of JS co-treatment in severe COVID-19 patients. JS co-treatment might reduce death rate and recovery time. Further large-scale clinical trials would be expected.</description><identifier>ISSN: 2210-8033</identifier><identifier>EISSN: 2210-8041</identifier><identifier>DOI: 10.1016/j.hermed.2022.100610</identifier><identifier>PMID: 36341465</identifier><language>eng</language><publisher>Netherlands: Elsevier GmbH</publisher><subject>Chinese medicine ; Clinical course ; Covid-19 ; Death rate ; Sars-cov-2</subject><ispartof>Journal of herbal medicine, 2022-12, Vol.36, p.100610-100610, Article 100610</ispartof><rights>2022 Elsevier GmbH</rights><rights>2022 Elsevier GmbH. All rights reserved.</rights><rights>2022 Elsevier GmbH. All rights reserved. 2022 Elsevier GmbH</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-4b1c6946229a6d67ce88304a4c11a30d031d29b06588bd2fc09e5367c3b9f6113</citedby><cites>FETCH-LOGICAL-c463t-4b1c6946229a6d67ce88304a4c11a30d031d29b06588bd2fc09e5367c3b9f6113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36341465$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Li, Pei-Chen</creatorcontrib><creatorcontrib>Wang, Hui-Sheng</creatorcontrib><creatorcontrib>Shibu, Marthandam Asokan</creatorcontrib><creatorcontrib>Wang, Jhen</creatorcontrib><creatorcontrib>Huang, Shiau-Huei</creatorcontrib><creatorcontrib>Wang, Jeng-Hung</creatorcontrib><creatorcontrib>Wang, Ji-Hung</creatorcontrib><creatorcontrib>Huang, Chih-Yang</creatorcontrib><creatorcontrib>Chiang, Chien-Yi</creatorcontrib><creatorcontrib>Lin, Yu-Jung</creatorcontrib><creatorcontrib>Ho, Tsung-Jung</creatorcontrib><creatorcontrib>Lin, Shinn-Zong</creatorcontrib><creatorcontrib>Chung, Hui-Chun</creatorcontrib><creatorcontrib>Yu, Hsin-Yuan</creatorcontrib><creatorcontrib>Su, San-Hua</creatorcontrib><creatorcontrib>Chou, Ying-Fang</creatorcontrib><creatorcontrib>Tai, Chia-Hui</creatorcontrib><creatorcontrib>Ding, Dah-Ching</creatorcontrib><creatorcontrib>Shih, Cheng Yen</creatorcontrib><title>Clinical course of patients with severe SARS-CoV-2 infection co-treatment with Jin Si Herbal Tea in Eastern Taiwan: A retrospective cohort study</title><title>Journal of herbal medicine</title><addtitle>J Herb Med</addtitle><description>Coronavirus disease-2019 (COVID-19) has affected more than 608 million people and has killed 6.5 million people in the world. A few studies showed traditional Chinese medicine can be beneficial for COVID-19 treatment. An herbal preparation Jin Si Herbal Tea (JS) was formulated with herbal extracts known for their potential to decrease spike protein and ACE2 interaction, 3CL, and TRPMSS2 protease activity, and thus aimed to evaluate the clinical course of JS co-treatment along with the usual treatment schedule given for severe COVID-19 patients.
This retrospective cohort study included patients with severe COVID-19 admitted to Hualien Tzu Chi Hospital between June and July 2021. All the patients were co-treated with JS and the primary outcome was death. The secondary outcomes included laboratory exam, Ct value, clinical course, and hospital stays. There were 10 patients recruited in this study and divided into < 70 years and ≧ 70 years groups (n = 5 in each group).
Older patients (≧70 years) had a higher Charlson Comorbidity Index, VACO index, and lower hemoglobin levels than < 70 years patients. The trend of lymphocyte count, LDH, D-dimer, and Ct value of non-survivors was not consistent with previous studies. The death rate was 20% and the recovery rate to mild illness in 14 days was 40%.
In conclusion, this is the first clinical study of JS co-treatment in severe COVID-19 patients. JS co-treatment might reduce death rate and recovery time. Further large-scale clinical trials would be expected.</description><subject>Chinese medicine</subject><subject>Clinical course</subject><subject>Covid-19</subject><subject>Death rate</subject><subject>Sars-cov-2</subject><issn>2210-8033</issn><issn>2210-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kc1uEzEUhS0EolXpGyDkJZtJ_Rd3hgVSFBVaVAmJBLaWx3OHOJrYwfak6lvwyNxoSoAN3tiyzz3X536EvOZsxhnXV9vZBtIOuplgQuAV05w9I-dCcFbVTPHnp7OUZ-Qy5y3DpZlQjL8kZ1JLxZWen5Ofy8EH7-xAXRxTBhp7urfFQyiZPviyoRkOkICuFl9W1TJ-qwT1oQdXfAxYU5UEtuxQPqk_-UBXnt5CatFzDRbV9MbmAinQtfUPNryjC5qgpJj3R5sDoM0mpkJzGbvHV-RFb4cMl0_7Bfn64Wa9vK3uP3-8Wy7uK6e0LJVqudON0kI0Vnf62kFdS6ascpxbyTomeSealul5Xbed6B1rYC5RJ9um15zLC_J-8t2PLQ7SYYJkB7NPfmfTo4nWm39fgt-Y7_FgGs31nAs0ePtkkOKPEXIxO58dDIMNEMdsxLWUSEcKiVI1SR2Gzgn6UxvOzJGn2ZqJpznyNBNPLHvz9xdPRb_p_ckAOKiDh2SyQ3IOOp9wtKaL_v8dfgEhKrPH</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Li, Pei-Chen</creator><creator>Wang, Hui-Sheng</creator><creator>Shibu, Marthandam Asokan</creator><creator>Wang, Jhen</creator><creator>Huang, Shiau-Huei</creator><creator>Wang, Jeng-Hung</creator><creator>Wang, Ji-Hung</creator><creator>Huang, Chih-Yang</creator><creator>Chiang, Chien-Yi</creator><creator>Lin, Yu-Jung</creator><creator>Ho, Tsung-Jung</creator><creator>Lin, Shinn-Zong</creator><creator>Chung, Hui-Chun</creator><creator>Yu, Hsin-Yuan</creator><creator>Su, San-Hua</creator><creator>Chou, Ying-Fang</creator><creator>Tai, Chia-Hui</creator><creator>Ding, Dah-Ching</creator><creator>Shih, Cheng Yen</creator><general>Elsevier GmbH</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221201</creationdate><title>Clinical course of patients with severe SARS-CoV-2 infection co-treatment with Jin Si Herbal Tea in Eastern Taiwan: A retrospective cohort study</title><author>Li, Pei-Chen ; Wang, Hui-Sheng ; Shibu, Marthandam Asokan ; Wang, Jhen ; Huang, Shiau-Huei ; Wang, Jeng-Hung ; Wang, Ji-Hung ; Huang, Chih-Yang ; Chiang, Chien-Yi ; Lin, Yu-Jung ; Ho, Tsung-Jung ; Lin, Shinn-Zong ; Chung, Hui-Chun ; Yu, Hsin-Yuan ; Su, San-Hua ; Chou, Ying-Fang ; Tai, Chia-Hui ; Ding, Dah-Ching ; Shih, Cheng Yen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-4b1c6946229a6d67ce88304a4c11a30d031d29b06588bd2fc09e5367c3b9f6113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Chinese medicine</topic><topic>Clinical course</topic><topic>Covid-19</topic><topic>Death rate</topic><topic>Sars-cov-2</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Li, Pei-Chen</creatorcontrib><creatorcontrib>Wang, Hui-Sheng</creatorcontrib><creatorcontrib>Shibu, Marthandam Asokan</creatorcontrib><creatorcontrib>Wang, Jhen</creatorcontrib><creatorcontrib>Huang, Shiau-Huei</creatorcontrib><creatorcontrib>Wang, Jeng-Hung</creatorcontrib><creatorcontrib>Wang, Ji-Hung</creatorcontrib><creatorcontrib>Huang, Chih-Yang</creatorcontrib><creatorcontrib>Chiang, Chien-Yi</creatorcontrib><creatorcontrib>Lin, Yu-Jung</creatorcontrib><creatorcontrib>Ho, Tsung-Jung</creatorcontrib><creatorcontrib>Lin, Shinn-Zong</creatorcontrib><creatorcontrib>Chung, Hui-Chun</creatorcontrib><creatorcontrib>Yu, Hsin-Yuan</creatorcontrib><creatorcontrib>Su, San-Hua</creatorcontrib><creatorcontrib>Chou, Ying-Fang</creatorcontrib><creatorcontrib>Tai, Chia-Hui</creatorcontrib><creatorcontrib>Ding, Dah-Ching</creatorcontrib><creatorcontrib>Shih, Cheng Yen</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of herbal medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Li, Pei-Chen</au><au>Wang, Hui-Sheng</au><au>Shibu, Marthandam Asokan</au><au>Wang, Jhen</au><au>Huang, Shiau-Huei</au><au>Wang, Jeng-Hung</au><au>Wang, Ji-Hung</au><au>Huang, Chih-Yang</au><au>Chiang, Chien-Yi</au><au>Lin, Yu-Jung</au><au>Ho, Tsung-Jung</au><au>Lin, Shinn-Zong</au><au>Chung, Hui-Chun</au><au>Yu, Hsin-Yuan</au><au>Su, San-Hua</au><au>Chou, Ying-Fang</au><au>Tai, Chia-Hui</au><au>Ding, Dah-Ching</au><au>Shih, Cheng Yen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical course of patients with severe SARS-CoV-2 infection co-treatment with Jin Si Herbal Tea in Eastern Taiwan: A retrospective cohort study</atitle><jtitle>Journal of herbal medicine</jtitle><addtitle>J Herb Med</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>36</volume><spage>100610</spage><epage>100610</epage><pages>100610-100610</pages><artnum>100610</artnum><issn>2210-8033</issn><eissn>2210-8041</eissn><abstract>Coronavirus disease-2019 (COVID-19) has affected more than 608 million people and has killed 6.5 million people in the world. A few studies showed traditional Chinese medicine can be beneficial for COVID-19 treatment. An herbal preparation Jin Si Herbal Tea (JS) was formulated with herbal extracts known for their potential to decrease spike protein and ACE2 interaction, 3CL, and TRPMSS2 protease activity, and thus aimed to evaluate the clinical course of JS co-treatment along with the usual treatment schedule given for severe COVID-19 patients.
This retrospective cohort study included patients with severe COVID-19 admitted to Hualien Tzu Chi Hospital between June and July 2021. All the patients were co-treated with JS and the primary outcome was death. The secondary outcomes included laboratory exam, Ct value, clinical course, and hospital stays. There were 10 patients recruited in this study and divided into < 70 years and ≧ 70 years groups (n = 5 in each group).
Older patients (≧70 years) had a higher Charlson Comorbidity Index, VACO index, and lower hemoglobin levels than < 70 years patients. The trend of lymphocyte count, LDH, D-dimer, and Ct value of non-survivors was not consistent with previous studies. The death rate was 20% and the recovery rate to mild illness in 14 days was 40%.
In conclusion, this is the first clinical study of JS co-treatment in severe COVID-19 patients. JS co-treatment might reduce death rate and recovery time. Further large-scale clinical trials would be expected.</abstract><cop>Netherlands</cop><pub>Elsevier GmbH</pub><pmid>36341465</pmid><doi>10.1016/j.hermed.2022.100610</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2210-8033 |
| ispartof | Journal of herbal medicine, 2022-12, Vol.36, p.100610-100610, Article 100610 |
| issn | 2210-8033 2210-8041 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9616512 |
| source | Alma/SFX Local Collection |
| subjects | Chinese medicine Clinical course Covid-19 Death rate Sars-cov-2 |
| title | Clinical course of patients with severe SARS-CoV-2 infection co-treatment with Jin Si Herbal Tea in Eastern Taiwan: A retrospective cohort study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T02%3A36%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20course%20of%20patients%20with%20severe%20SARS-CoV-2%20infection%20co-treatment%20with%20Jin%20Si%20Herbal%20Tea%20in%20Eastern%20Taiwan:%20A%20retrospective%20cohort%20study&rft.jtitle=Journal%20of%20herbal%20medicine&rft.au=Li,%20Pei-Chen&rft.date=2022-12-01&rft.volume=36&rft.spage=100610&rft.epage=100610&rft.pages=100610-100610&rft.artnum=100610&rft.issn=2210-8033&rft.eissn=2210-8041&rft_id=info:doi/10.1016/j.hermed.2022.100610&rft_dat=%3Cproquest_pubme%3E2733202323%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2733202323&rft_id=info:pmid/36341465&rft_els_id=S2210803322000793&rfr_iscdi=true |